Health Economics of a Bioactive Beta-Glucan Gel
Keith F Cutting, Clinical Research Consultant, Hertfordshire, UK - email: firstname.lastname@example.org
A Bioactive Beta-Glucan Gel containing soluble Beta-Glucan (SBG), a natural polymer, is intend- ed to be used on stalled dermal wounds where standard of care has failed. The demand for intervention in healthcare will always exceed supply, therefore evidence in re- spect of effectiveness and cost-effectiveness, is vital.
Data is presented from two studies
1.) Zykova et al, 2014
In an RCT 60 DFU patients (Zykova et al, 2014) received either standard of care plus soluble beta-glucan or
standard care plus a hydrogel dressing, three times weekly for up to 12 weeks.
This data was used to populate a cost-effectiveness model. Extending the analysis to cover an annual budget cycle using a Markov extrapolation shows that the mean ‘expected weeks healed’ for patients treated with Bioactive Beta- Glucan Gel was 34.4 compared with 24.7 with standard of care.
The mean ‘weeks of treatment’ with Bioactive Beta-Glucan Gel was 17.6 compared to 27.4 for standard of care with an incremental benet of 9.7 weeks. Over the annual period, Bioactive Beta-Glucan Gel is expected to be cost saving (approximately £500 per patient) and is the dominant treatment option.
2.) King et al, 2016
In a clinical evaluation over a period of 12 weeks (King et al, 2016), wound response and cost of care were calculated in 26 wounds (DFU, LU and PU) where healing was stalled for at least 4 weeks prior to enrolment.
7 patients’ wounds healed within 12 weeks. In all but 1 patient, treatment with Bioactive Beta-Glucan Gel is shown to be considerably less expensive than prior standard of care.
3 additional wounds healed after the initial 12 week period having been stalled prior to Bioactive Beta-Glucan Gel therapy.
8 wounds showed a surface area reduction of >50%, and 5 wounds showed a 10-50% reduction.
Across the 26 patients, costs over 12 weeks with Bioactive Beta-Glucan Gel were lower than the prior treatment in all but 4 cases. The accumulated prior treatment cost for the total cohort is conservatively calculated to £22,901, whereas the accumulated total cost during the Bioactive Beta-Glucan Gel treatment period was £11,657 of which £5,520 is the direct Bioactive Beta-Glucan Gel cost.
In these 26 patients, the accumulated total cost of using Bioactive Beta-Glucan Gel, in addition to the standard of care cost, is calcu- lated to about £5,520, which is less than the total pre-treatment cost of patient no. 22 alone with a 6 year non-healing wound history.
Recent clinical and economic ndings demonstrate that a Bioactive Beta-Glucan Gel provides evidence of effectiveness and cost- effectiveness in a variety of wound types.
1. Zykova et al. Journal of Diabetes Investigation 2014;5(4):392-99.
2. King, B. et al. 2016 - publication submitted to JWC